• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Heptapeptide ligands against receptor-binding sites of influenza hemagglutinin toward anti-influenza therapy

tetano

Editor, Senior Moderator
Bioorg Med Chem. 2016 Jan 21. pii: S0968-0896(16)30039-6. doi: 10.1016/j.bmc.2016.01.039. [Epub ahead of print]
[h=1]Heptapeptide ligands against receptor-binding sites of influenza hemagglutinin toward anti-influenza therapy.[/h] Matsubara T[SUP]1[/SUP], Onishi A[SUP]1[/SUP], Yamaguchi D[SUP]1[/SUP], Sato T[SUP]2[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] The initial attachment of influenza virus to cells is the binding of hemagglutinin (HA) to the sialyloligosaccharide receptor; therefore, the small molecules that inhibit the sugar-protein interaction are promising as HA inhibitors to prevent the infection. We herein demonstrate that sialic acid-mimic heptapeptides are identified through a selection from a primary library against influenza virus HA. In order to obtain lead peptides, an affinity selection from a phage-displayed random heptapeptide library was performed with the HAs of the H1 and H3 strains, and two kinds of the HA-binding peptides were identified. The binding of the peptides to HAs was inhibited in the presence of sialic acid, and plaque assays indicated that the corresponding N-stearoyl peptide strongly inhibited infections by the A/Aichi/2/68 (H3N2) strain of the virus. Alanine scanning of the peptides indicated that arginine and proline were responsible for binding. The affinities of several mutant peptides with single-amino-acid substitutions against H3 HA were determined, and corresponding docking studies were performed. A Spearman analysis revealed a correlation between the affinity of the peptides and the docking study. These results provide a practicable method to design of peptide-based HA inhibitors that are promising as anti-influenza drugs.
Copyright ? 2016 Elsevier Ltd. All rights reserved.


[h=4]KEYWORDS:[/h] Hemagglutinin; Heptapeptide library; Peptide drug; Phage display; Sialic acid-mimic

PMID: 26833245 [PubMed - as supplied by publisher]
 
Back
Top Bottom